PMID- 32824427
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 12
IP  - 8
DP  - 2020 Aug 17
TI  - Time to Next Treatment as a Meaningful Endpoint for Trials of Primary Cutaneous 
      Lymphoma.
LID - 10.3390/cancers12082311 [doi]
LID - 2311
AB  - Time to next treatment (TTNT) is an emerging endpoint in clinical studies of 
      primary cutaneous T-cell lymphomas (CTCL), with utility as a surrogate marker for 
      the "duration of clinical benefit". TTNT provides a highly clinically meaningful 
      endpoint that uniquely reflects not only the duration of treatment efficacy on 
      disease and symptom control, but also incorporates the patient experience by 
      accounting for patient compliance and tolerance to the studied therapy(s). Given 
      the distinct challenges of pin-pointing the exact date of progression in patients 
      with multi-compartmental CTCL, TTNT overcomes many of the shortcomings of 
      conventional, disease-focused, clinical endpoints in primary CTCL research. 
      Although widely accepted in clinical research for numerous other incurable 
      malignancies, TTNT currently lacks a standardised definition. In this paper, we 
      describe the value of TTNT as a clinical endpoint, review the applications of 
      TTNT in primary CTCL research, and propose a standardised definition of TTNT to 
      be applied in future clinical research of primary CTCL therapies.
FAU - Campbell, Belinda A
AU  - Campbell BA
AUID- ORCID: 0000-0002-7316-8723
AD  - Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC 
      3000, Australia.
AD  - Department of Clinical Pathology, The University of Melbourne, Parkville, VIC 
      3010, Australia.
FAU - Scarisbrick, Julia J
AU  - Scarisbrick JJ
AUID- ORCID: 0000-0002-8011-4408
AD  - Department of Dermatology, University Hospital Birmingham, Birmingham B15 2TH, 
      UK.
FAU - Kim, Youn H
AU  - Kim YH
AD  - Department of Dermatology, Stanford Cancer Institute, Stanford, CA 94305, USA.
FAU - Wilcox, Ryan A
AU  - Wilcox RA
AD  - Division of Hematology and Medical Oncology, Department of Internal Medicine, 
      University of Michigan Rogel Cancer Center, Ann Arbor, MI 48109, USA.
FAU - McCormack, Christopher
AU  - McCormack C
AD  - Department of Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC 
      3000, Australia.
AD  - Department of Dermatology, St Vincent's Hospital Melbourne, Fitzroy, VIC 3065, 
      Australia.
FAU - Prince, H Miles
AU  - Prince HM
AD  - Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal 
      Melbourne Hospital, Melbourne, VIC 3000, Australia.
AD  - Sir Peter MacCallum Department of Oncology, The University of Melbourne, 
      Parkville, VIC 3010, Australia.
LA  - eng
PT  - Journal Article
DEP - 20200817
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC7463470
OTO - NOTNLM
OT  - clinical endpoint
OT  - clinical trials
OT  - primary cutaneous lymphomas
OT  - study design
OT  - time to next treatment
COIS- The authors declare no conflict of interest.
EDAT- 2020/08/23 06:00
MHDA- 2020/08/23 06:01
PMCR- 2020/08/17
CRDT- 2020/08/23 06:00
PHST- 2020/07/01 00:00 [received]
PHST- 2020/08/09 00:00 [revised]
PHST- 2020/08/11 00:00 [accepted]
PHST- 2020/08/23 06:00 [entrez]
PHST- 2020/08/23 06:00 [pubmed]
PHST- 2020/08/23 06:01 [medline]
PHST- 2020/08/17 00:00 [pmc-release]
AID - cancers12082311 [pii]
AID - cancers-12-02311 [pii]
AID - 10.3390/cancers12082311 [doi]
PST - epublish
SO  - Cancers (Basel). 2020 Aug 17;12(8):2311. doi: 10.3390/cancers12082311.